Bayer and Bicycle Therapeutics Limited, a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle), have entered a strategic collaboration to discover, develop, manufacture, and commercialize Bicycle radio conjugates for multiple agreed upon oncology targets. Under the terms of the agreement, the two companies will collaborate on the development of bicyclic peptides for multiple oncology targets. Bicycle ai...